Company: CERO
Filing Date: 2025-11-28
Form Type: DEF 14A
Source: 0001213900-25-115783
Chunk: 49

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-28
Form: DEF 14A
Chunk 49
---
 executive officers (three executive officers)                   |     |  38,251 |
| All former executive officers (three executive officers)                    |     |       — |
| All current non-employee directors                                          |     |  21,376 |
| All employees and consultants (other than executive officers and directors) |     |  14,524 |

____________ (1)Excludes 264 options granted under the Amended Plan which were forfeited on September 30, 2024. (2)Excludes 666 options granted under the Amended Plan which were forfeited on September 30, 2024. (3)Excludes 248 options granted under the Amended Plan which were forfeited on September 30, 2024. (4)Excludes 428 options granted under the Amended Plan which were forfeited on September 23, 2024. If the Company’s stockholders approve this proposal, the Amendment will become effective as of the date on which the Amendment is approved by stockholders, and awards may be granted under the Amended Plan. If the Company’s stockholders do not approve the Amendment, the Company will continue to grant awards under the existing Plan as long as shares are available for such purpose. Interests of Directors and Executive Officers Our current directors and executive officers have substantial interests in the matters set forth in this proposal since equity awards may be granted to them under the Amended Plan. Vote Required; Board Recommendation The affirmative vote of the holders of a majority of the votes cast at the Special Meeting will be required to approve this proposal. Abstentions and broker non -voteswill have no effect on the outcome of this proposal.

| THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE APPROVAL OF THE 2024 PLAN AS AMENDED TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE FOR ISSUANCE UNDER THE 2024 PLAN AND THE NUMBER OF SHARES THAT MAY BE ISSUED PURSUANT TO INCENTIVE STOCK OPTIONS BY AN ADDITIONAL 32,000,000 SHARES. |     | ✓ |

26

PROPOSAL NO. 4: ADJOURNMENT PROPOSAL Overview If the Company fails to receive a sufficient number of votes to approve Proposal Nos.1,2, or3, the Company may propose to adjourn or postpone the Special Meeting. The Company currently does not intend to propose an adjournment or postponement at the Special Meeting if there are sufficient votes to approve Proposal Nos